Agios Pharmaceuticals, Inc. AGIO saw a big move last session, as the company's shares fell nearly 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for AGIO as the stock is now up around 16.0% in the past one-month time frame.
The company has seen a flat track record when it comes to current year estimate revisions over the past few weeks. The consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
AGIO currently has a Zacks Rank #5 (Sell) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the health care sector include Quidel Corp. QDEL, Venaxis, Inc. APPY and William Demant Holding A/S (WILYY). All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
The company has seen a flat track record when it comes to current year estimate revisions over the past few weeks. The consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
AGIO currently has a Zacks Rank #5 (Sell) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the health care sector include Quidel Corp. QDEL, Venaxis, Inc. APPY and William Demant Holding A/S (WILYY). All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
AGIOS PHARMACT AGIO: Free Stock Analysis Report
VENAXIS INC APPY: Get Free Report
QUIDEL CORP QDEL: Free Stock Analysis Report
WILLIAM DEMANT (WILYY): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
